Review article: gastro‐oesophageal reflux disease – the health economic implications
Open Access
- 24 July 2005
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 22 (s1) , 20-31
Abstract
Summary: For the vast majority of patients with gastro‐oesophageal reflux disease appropriate care involves the management of symptoms with lifestyle advice and drugs. However, there is dissension about the appropriate use of endoscopy, whether drugs should be stepped up or down according to potency, how long drugs should be used for, the role of lifestyle advice, and, related to this, the role of patients’ lifestyle choices.This exploration of the economics of gastro‐oesophageal reflux disease reviews its cost burden to the UK, assesses published economic models for their strengths and weaknesses and examines current recommendations for gastro‐oesophageal reflux disease management from a socioeconomic perspective. Drugs prescribed predominantly for dyspepsia cost the UK National Health Service a projected £625 million in 2004, 7% of the primary care prescribing budget. When general practitioners consultations, endoscopies, over‐the‐counter sales and sickness absences are included the UK cost rises to £1.5 billion: approximately half of this cost can be ascribed to gastro‐oesophageal reflux disease. Emphasis upon regular review and stepping down treatment (while maintaining adequate symptom relief) is both clinically appropriate and resource efficient. Other cost‐effectiveness issues largely lack objective answers because investment in treatment for gastro‐oesophageal reflux disease depends upon how much more, at the margin, society wishes to invest for further but diminishing symptom relief.Keywords
This publication has 35 references indexed in Scilit:
- Esomeprazole 20 mg on‐demand is more acceptable to patients than continuous lansoprazole 15 mg in the long‐term maintenance of endoscopy‐negative gastro‐oesophageal reflux patients: the COMMAND StudyAlimentary Pharmacology & Therapeutics, 2004
- Costs and efficacy of three different esomeprazole treatment strategies for long‐term management of gastro‐oesophageal reflux symptoms in primary careAlimentary Pharmacology & Therapeutics, 2004
- On-demand rabeprazole therapy provides heartburn control in long-term management of nonerosive reflux disease (NERD)Gastroenterology, 2003
- On-demand therapy with pantoprazole 20 mg as effective long-term managemnt of patients suffering from mild GERDGastroenterology, 2003
- On-Demand maintenance therapy with rabeprazole (RAB) 10 mg: an effective alternative to continuous therapy for patients with frequent gastroesophageal reflux symptomatic relapseGastroenterology, 2003
- Systematic review: patient‐centred endpoints in economic evaluations of gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 2002
- How do younger patients view long-term treatment with proton pump inhibitors?Perspectives in Public Health, 2002
- Economic Evaluation of Long Term Management Strategies for Erosive OesophagitisPharmacoEconomics, 1999
- Assessing the Cost-effectiveness of Medical Treatments in Acid-related Diseases: The Markov Chain Approach Applied to a Comparison between Intermittent and Maintenance Treatment of Reflux EsophagitisScandinavian Journal of Gastroenterology, 1993
- H2 antagonists in the treatment of reflux oesophagitis: can physiological studies predict the response?Gut, 1987